- Home
- PVL vs MIRA Comparison
PVL vs MIRA Comparison
Compare PVL & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PVL | MIRA |
|---|---|---|
| Founded | 2011 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.8M | 53.2M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | PVL | MIRA |
|---|---|---|
| Price | $1.88 | $1.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 131.4K | 125.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 10.00% | N/A |
| EPS Growth | N/A | ★ 20.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.30 | $0.81 |
| 52 Week High | $2.04 | $2.45 |
Technical Indicators
Market Signals| Indicator | PVL | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 61.12 | 45.43 |
| Support Level | $1.72 | $1.12 |
| Resistance Level | $1.89 | $1.35 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 82.81 | 45.96 |
Price Performance
Historical ComparisonAbout PVL Permianville Royalty Trust Trust Units
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.